Navitor Pharmaceuticals
CAMBRIDGE, MA · Founded 2010 · CIK 0001588059 · Biotech · Private
mTORC1 activator small molecules for rare metabolic disorders
navitorpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $65M
- 5 Form D · May 2020
- 77 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 18 granted · 22 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20132014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,231,974 | |
| Private capital raised | Form D · SEC | $12,000,001 | |
| Private capital raised | Form D · SEC | $11,250,002 | |
| Private capital raised | Form D · SEC | $11,250,003 | |
| Private capital raised | Form D · SEC | $20,186,771 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1750 | ASAKE BIOTECHNOLOGY, LLC | — | — |
| 1751 | ANTHROBIO, INC. | — | — |
| 1752 | Torque Medical Holdings, LLC | — | $4.7M |
| 1753 | Navitor Pharmaceuticals | — | $65M |
| 1754 | Aviceda Therapeutics | — | $99M |
| 1755 | PROTABIT, LLC | — | — |
| 1756 | LAMNOTHERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Kevin BittermanDirector
- Barry BurgdorfDirector
- Alan CraneDirector
- John CreecyDirector · Executive Officer
- Rajeev DadooDirector
- Jean-Francois FormelaDirector
- Paul FriedmanDirector
- Paul Friedman, M.D.Director
- Brian GallagherDirector
- Brian Gallagher, Ph.D.Director
- David GoldfarbDirector · Executive Officer
- Thomas HughesDirector · Executive Officer
- Richard LundbergExecutive Officer
- Rick LundbergExecutive Officer
- David MaddenDirector
- Marian NakadaDirector
- Marian Nakada, Ph.D.Director
- Vinzenz PloererDirector
- Georg VlasukDirector
- George VlasukDirector · Executive Officer
Patents
- MODULATORS OF mTORC1 ACTIVITY AND USES THEREOFapplication
- Modulators Of SESTRIN-GATOR2 Interaction And Uses Thereofapplication
- Modulators Of SESTRIN-GATOR2 Interaction And Uses Thereofapplication
- Methods Of Treatment Using An MTORC1 Modulatorgranted
- Modulators Of SESTRIN-GATOR2 Interaction And Uses Thereofgranted
- Modulators Of SESTRIN-GATOR2 Interaction And Uses Thereofgranted
- Polymorphic Compounds And Uses Thereofapplication
- Polymorphic Compounds And Uses Thereofgranted
- METHODS OF TREATMENT USING AN mTORC1 MODULATORgranted
- Polymorphic Compounds And Uses Thereofgranted
- Modulators Of SESTRIN-GATOR2 Interaction And Uses Thereofgranted
- Polymorphic Compounds And Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.